STAGE II BLADDER CANCER AJCC V8
Clinical trials for STAGE II BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE II BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE II BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts bladder cancer treatment in major trial
Disease control OngoingThis Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…
Matched conditions: STAGE II BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Bladder cancer drug combo trial pulled before it even started
Disease control TerminatedThis trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…
Matched conditions: STAGE II BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Bladder cancer survivors share how treatment changes their daily lives
Knowledge-focused OngoingThis study follows 204 people with bladder cancer to see how their quality of life changes after treatment like surgery or radiation. Participants fill out surveys about physical function, pain, fatigue, anxiety, and bladder, bowel, and sexual health. The goal is to understand ho…
Matched conditions: STAGE II BLADDER CANCER AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC